Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2020 / N 2

Лекарственно-индуцированное увеличение массы тела
О.Д. Остроумова, Ю.И. Сапожникова, А.И. Кочетков, А.В. Стародубова

Список литературы

1. Sheehan AH. Weight gain. In: Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018: 1171-7.
2. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight changes, and coronary heart disease in women: risk within the ‘normal’ weight range. JAMA 1995 Feb;273(6):461-5.
3. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. American Journal of Epidemiology 1995 Jun;141(12):1117-27.
4. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine 1995 Apr;122(7):481-6.
5. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Obesity Research 1998 Sep;6(Suppl 2):51S-209S.
6. Choong E, Bondolfi G, Etter M, Jermann F, Aubry JM, Bartolomei J, Gholam-Rezaee M, Eap CB. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. Journal of Psychiatric Research 2012 Apr;46(4):540-8.
7. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007 Jul;100(7):395-404.
8. Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RA. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, Metabolic Syndrome and Obesity 2018 Aug;11:427-38.
9. Lau DC, Teoh H. Impact of current and emerging glucose-lowering drugs on body weight in type 2 diabetes. Canadian Journal of Diabetes 2015 Dec;39(Suppl 5):S148-54.
10. Obesity Action Coalition. Kyle T, Kuehl B. Prescription medications & weight gain. What you need to know. 2013 Summer.
11. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Safety 2001;24(13):969-78.
12. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. The Journal of Clinical Psychiatry 2004 Oct;65(10):1365-71.
13. Horber FF, Zürcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. The American Journal of Clinical Nutrition 1986 May;43(5):758-69.
14. Actos package insert. Deerfield, IL: Takeda Pharmaceuticals America Inc; 2013.
15. Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmächer T. Early prediction of changes in weight during six weeks of treatment with antidepressants. Journal of Psychiatric Research. 2004 Sep-Oct;38(5):485-9.
16. Saddichha S, Ameen S, Akkhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Journal of Clinical Psychopharmacology 2008 Feb;28(1):27-31.
17. Himmerich H, Minkwitz J, Kirkby KC. Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocrine, Metabolism & Immune Disorders Drug Targets 2015;15(4):252-60.
18. Reynolds GP, Hill MK, Kirk SL. The 5-HT2C receptor and antipsychotic-induced weight gain-mechanisms and genetics. Journal of Psychopharmacology (Oxford, England) 2006 Jul;20(Suppl 4):15-8.
19. Yu H, Wang L, Lv L, Ma C, Du B, Lu T, Jin C, Yan H, Yang Y, Li W, Ruan Y, Zhang H, Zhang H, Mi W, Mowry B, Ma W, Li K, Zhang D, Yue W. Genome-wide association study suggested the PTPRD polymorphisms were associated with weight gain effects of atypical antipsychotic medications. Schizophrenia Bulletin 2015 May;42(3):814-23.
20. Czerwensky F, Leucht S, Steimer W. Association of the common MC4R rs117782313 polymorphism with antipsychotic-related weight gain. Journal of Clinical Psychopharmacology 2013 Feb;33(1):74-9.
21. Denmark-Wahnefried W, Rimer B, Winer EP. Weight gain in women diagnosed with breast cancer. Journal of American Dietetic Association 1997 May;97(5):519-26, 529; quiz 527-8.
22. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. The Journal of Adolescent Health 1999 Jun;24(6):433-6.
23. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. The Journal of Clinical Psychiatry 2004 Apr;65(4):471-7.
24. Bonfioli E, Berti L, Gross C, Muraro F, Burti L. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomized controlled trials. BMC Psychiatry 2012 Jul;12:78.
25. Gabriele JM, Dubbert PM, Reeves RR. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obesity Reviews 2009 Jul;10(4):442-55.
26. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RE, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, Jordan HS, Kendall KA, Lux LJ, Mentor-Marcel R, Morgan LC, Trisolini MG, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli CF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014 Jun;129(25 Suppl 2):S102-38.
27. Das C, Mendez G, Jagasis S, Labbate L. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Annals of Clinical Psychiatry 2012 Aug;24(3):225-39.
28. Masopust J, Tuma I, Libiger J. Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment. Neuro Endocrinology Letters 2008 Aug;29(4):435-7.
29. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. The American Journal of Psychiatry 2002 Jun;159(6):1058-60.
30. Ghanizadeh A, Nikseresht MS, Sahraian A. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophrenia Research 2013 Jun;147(1):110-5.
31. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD; Endocrine Society. Pharmacological management of obesity: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 2015 Feb;100(2):342-62.
32. Henderson DC, Fan X, Copeland PM, Sharma B, Borba C, Boxill R, Freudenreich O, Cather C, Evins AE, Goff D. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of Clinical Psychopharmacology 2009 Apr;29(2):165-9.
33. Englisch S, Weinbrenner A, Inta D, Zink M. Aripiprazole for the management of olanzapine-induced weight gain. Pharmacopsychiatry 2009 Jul;42(4):166-7.
34. Ranjbar S, Pai NB, Deng C. The association of antidepressant medication and body weight gain. Online Journal of Health and Allied Sciences 2013;12(1):1-9.
35. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. European Neuropsychopharmacology 2003 Mar;13(2):81-5.
36. Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology 2004 Aug;14(4):332-6.
37. Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. International Clinical Psychopharmacology 2012 Mar;27(2):69-75.
38. Mahmood S, Booker I, Huang J, Coleman C. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. Journal of Clinical Psychopharmacology 2013 Feb;33(1):90-4.
39. Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. Atypical antipsychotic induced weight gain: pathophysiology and management. Annals of Clinical Psychiatry 2004 Apr-Jun;16(2):75-85.
40. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. The Journal of Clinical Psychiatry 2004;65(Suppl 18):13-26.
41. Henderson DC. Weight gain with atypical antipsychotics: evidence and insights. The Journal of Clinical Psychiatry 2007;68(Suppl 12):18-26.
42. Werneke U, Taylor D, Sanders TA. Behavioral interventions for antipsychotic-induced appetite changes. Current Psychiatry Reports 2013 Mar;15(3):347.

References

1. Sheehan AH. Weight gain. In: Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018: 1171-7.
2. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight changes, and coronary heart disease in women: risk within the ‘normal’ weight range. JAMA 1995 Feb;273(6):461-5.
3. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. American Journal of Epidemiology 1995 Jun;141(12):1117-27.
4. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine 1995 Apr;122(7):481-6.
5. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. Obesity Research 1998 Sep;6(Suppl 2):51S-209S.
6. Choong E, Bondolfi G, Etter M, Jermann F, Aubry JM, Bartolomei J, Gholam-Rezaee M, Eap CB. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. Journal of Psychiatric Research 2012 Apr;46(4):540-8.
7. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 2007 Jul;100(7):395-404.
8. Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RA. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, Metabolic Syndrome and Obesity 2018 Aug;11:427-38.
9. Lau DC, Teoh H. Impact of current and emerging glucose-lowering drugs on body weight in type 2 diabetes. Canadian Journal of Diabetes 2015 Dec;39(Suppl 5):S148-54.
10. Obesity Action Coalition. Kyle T, Kuehl B. Prescription medications & weight gain. What you need to know. 2013 Summer.
11. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Safety 2001;24(13):969-78.
12. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. The Journal of Clinical Psychiatry 2004 Oct;65(10):1365-71.
13. Horber FF, Zürcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. The American Journal of Clinical Nutrition 1986 May;43(5):758-69.
14. Actos package insert. Deerfield, IL: Takeda Pharmaceuticals America Inc; 2013.
15. Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmächer T. Early prediction of changes in weight during six weeks of treatment with antidepressants. Journal of Psychiatric Research. 2004 Sep-Oct;38(5):485-9.
16. Saddichha S, Ameen S, Akkhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Journal of Clinical Psychopharmacology 2008 Feb;28(1):27-31.
17. Himmerich H, Minkwitz J, Kirkby KC. Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocrine, Metabolism & Immune Disorders Drug Targets 2015;15(4):252-60.
18. Reynolds GP, Hill MK, Kirk SL. The 5-HT2C receptor and antipsychotic-induced weight gain-mechanisms and genetics. Journal of Psychopharmacology (Oxford, England) 2006 Jul;20(Suppl 4):15-8.
19. Yu H, Wang L, Lv L, Ma C, Du B, Lu T, Jin C, Yan H, Yang Y, Li W, Ruan Y, Zhang H, Zhang H, Mi W, Mowry B, Ma W, Li K, Zhang D, Yue W. Genome-wide association study suggested the PTPRD polymorphisms were associated with weight gain effects of atypical antipsychotic medications. Schizophrenia Bulletin 2015 May;42(3):814-23.
20. Czerwensky F, Leucht S, Steimer W. Association of the common MC4R rs117782313 polymorphism with antipsychotic-related weight gain. Journal of Clinical Psychopharmacology 2013 Feb;33(1):74-9.
21. Denmark-Wahnefried W, Rimer B, Winer EP. Weight gain in women diagnosed with breast cancer. Journal of American Dietetic Association 1997 May;97(5):519-26, 529; quiz 527-8.
22. Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. The Journal of Adolescent Health 1999 Jun;24(6):433-6.
23. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. The Journal of Clinical Psychiatry 2004 Apr;65(4):471-7.
24. Bonfioli E, Berti L, Gross C, Muraro F, Burti L. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomized controlled trials. BMC Psychiatry 2012 Jul;12:78.
25. Gabriele JM, Dubbert PM, Reeves RR. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obesity Reviews 2009 Jul;10(4):442-55.
26. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RE, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, Jordan HS, Kendall KA, Lux LJ, Mentor-Marcel R, Morgan LC, Trisolini MG, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli CF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014 Jun;129(25 Suppl 2):S102-38.
27. Das C, Mendez G, Jagasis S, Labbate L. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Annals of Clinical Psychiatry 2012 Aug;24(3):225-39.
28. Masopust J, Tuma I, Libiger J. Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment. Neuro Endocrinology Letters 2008 Aug;29(4):435-7.
29. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. The American Journal of Psychiatry 2002 Jun;159(6):1058-60.
30. Ghanizadeh A, Nikseresht MS, Sahraian A. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophrenia Research 2013 Jun;147(1):110-5.
31. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD; Endocrine Society. Pharmacological management of obesity: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 2015 Feb;100(2):342-62.
32. Henderson DC, Fan X, Copeland PM, Sharma B, Borba C, Boxill R, Freudenreich O, Cather C, Evins AE, Goff D. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of Clinical Psychopharmacology 2009 Apr;29(2):165-9.
33. Englisch S, Weinbrenner A, Inta D, Zink M. Aripiprazole for the management of olanzapine-induced weight gain. Pharmacopsychiatry 2009 Jul;42(4):166-7.
34. Ranjbar S, Pai NB, Deng C. The association of antidepressant medication and body weight gain. Online Journal of Health and Allied Sciences 2013;12(1):1-9.
35. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. European Neuropsychopharmacology 2003 Mar;13(2):81-5.
36. Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. European Neuropsychopharmacology 2004 Aug;14(4):332-6.
37. Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. International Clinical Psychopharmacology 2012 Mar;27(2):69-75.
38. Mahmood S, Booker I, Huang J, Coleman C. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. Journal of Clinical Psychopharmacology 2013 Feb;33(1):90-4.
39. Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. Atypical antipsychotic induced weight gain: pathophysiology and management. Annals of Clinical Psychiatry 2004 Apr-Jun;16(2):75-85.
40. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. The Journal of Clinical Psychiatry 2004;65(Suppl 18):13-26.
41. Henderson DC. Weight gain with atypical antipsychotics: evidence and insights. The Journal of Clinical Psychiatry 2007;68(Suppl 12):18-26.
42. Werneke U, Taylor D, Sanders TA. Behavioral interventions for antipsychotic-induced appetite changes. Current Psychiatry Reports 2013 Mar;15(3):347.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]